An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration

Registry ID

EUCTR2008-002101-39

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research & Development Limited

Start date

2008-09-25

Completion date

2009-09-09

Last update

2026-08-16

Conditions

• Neovascular age-related macular degeneration

Summary

To determine the systemic and local safety and tolerability of repeat topical ocular doses of pazopanib when administered daily to adult subjects with CNV due to neovascular AMD

Locations

• , , Italy
• , , Belgium

Related clinical trials

• Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD

View on source registry